Abstracts tagged "Fibroblasts, Other"

Abstract Number: 0516 • ACR Convergence 2021
Dual Fibroblast Transdifferentiation Mediated by Type I Interferon: Application to Anti-Ro Mediated Congenital Heart Block
Christina Firl¹, Miao Chang², Jill Buyon³ and Robert Clancy¹, ¹NYU Grossman School of Medicine, New York, NY, ²NYU Langone Health, New York, NY, ³NYU School of Medicine, New York, NY
Background/Purpose: Linking inflammation to fibrosis, a common end stage feature of many autoantibody mediated rheumatic diseases, remains a challenge. Indeed the signature hallmark of anti-Ro…
Abstract Number: 1917 • ACR Convergence 2021
Sputum TGF-β1 Is Elevated in Subclinical and Clinically Significant Rheumatoid Arthritis-Associated Interstitial Lung Disease and Correlates with Soluble IL-6R Levels
Timothy Wilson¹, Kevin Deane², Joyce Lee¹, Christopher Collora³, Marie Feser³, Mariana Kaplan⁴, Joshua Solomon⁵ and Kristen Demoruelle⁶, ¹University of Colorado, Denver, CO, ²University of Colorado Denver, Denver, CO, ³University of Colorado Denver, Aurora, CO, ⁴National Institutes of Health, Bethesda, MD, ⁵National Jewish Health, Denver, CO, ⁶University of Colorado Anschutz Medical Campus, Aurora, CO
Background/Purpose: Increased levels of transforming growth factor β1 (TGF-β1) in the lung have been implicated in the pathogenesis of several fibrotic lung diseases, but their…
Abstract Number: 0395 • ACR Convergence 2020
African Ancestry-Specific Variants Regulate TGFB3 Expression in Systemic Sclerosis
Julia Hartman¹, Andrea Conte², Chloe Borden³, Urvashi Kaundal⁴, Yongbing Zhao², Sarah Safran⁵, Ami Shah⁶, Maureen Mayes⁷, Ayo Doumatey⁸, Amy Bentley⁹, Daniel Shriner⁸, Robyn Domsic¹⁰, Thomas Medsger¹¹, Paula Ramos¹², Richard Silver¹³, Virginia Steen¹⁴, John Varga¹⁵, Vivien Hsu¹⁶, Lesley Ann Saketkoo¹⁷, Elena Schiopu¹⁸, Dinesh Khanna¹⁹, Jessica Gordon²⁰, Lindsey Criswell²¹, Heather Gladue²², Chris Derk²³, Elana Bernstein²⁴, S. Louis Bridges²⁵, Victoria Shanmugam²⁶, Kathleen Kolstad²⁷, Lorinda Chung²⁸, Suzanne Kafaja²⁹, Reem Jan³⁰, Marcin Trojanowski³¹, Avram Goldberg³², Benjamin Korman³³, Monique Hinchcliff³⁴, Settara Chandrasekharappa⁸, Stefania Dell'Orso³, Adebowale Adeyemo⁸, Charles Rotimi⁸, Elaine Remmers³⁵, Fredrick Wigley³⁶, Daniel Kastner³⁵, Francesco Boin³⁷, Rafael Casellas² and Pravitt Gourh⁴, ¹National Institute of Arthritis and Musculoskeletal and Skin Diseases, NIH, Washington, DC, ²National Institute of Arthritis and Musculoskeletal and Skin Diseases, Bethesda, ³National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), NIH, Bethesda, MD, ⁴National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), NIH, Bethesda, ⁵National Institute of Arthritis and Musculoskeletal and Skin Diseases, New York, NY, ⁶Johns Hopkins University School of Medicine, Ellicott City, MD, ⁷University of Texas Houston McGovern Medical School, Division of Rheumatology and Clinical Immunogenetics, Houston, TX, ⁸National Human Genome Research Institute, Bethesda, ⁹National Human Genome Research Institute (NHGRI), NIH, Bethedsa, MD, ¹⁰University of Pittsburgh School of Medicine, Pittsburgh, PA, ¹¹University of Pittsburgh School of Medicine, Verona, PA, ¹²Medical University of South Carolina, Charleston, SC, ¹³Medical University of South Carolina, Charleston, ¹⁴Division of Rheumatology, Department of Medicine, MedStar Georgetown University Hospital, Washington, DC, ¹⁵Northwestern University, Chicago, IL, ¹⁶Rutgers-RWJ Medical School, South Plainfield, NJ, ¹⁷Scleroderma Patient Care and Research Center, Tulane University, New Orleans, LA, ¹⁸Michigan Medicine, Ann Arbor, MI, ¹⁹University of Michigan, Ann Arbor, MI, ²⁰Hospital for Special Surgery, New York, NY, ²¹Rosalind Russell/Ephraim P. Engleman Rheumatology Research Center, University of California San Francisco, San Francisco, CA, ²²Arthritis and Osteoporosis Consultants of the Carolinas, Charlotte, NC, ²³University of Pennsylvania, Philadelphia, PA, ²⁴Columbia University, New York, NY, ²⁵University of Alabama at Birmingham, Mountain Brk, AL, ²⁶The George Washington University, Washington, DC, ²⁷Division of Immunology & Rheumatology, Stanford University School of Medicine, Palo Alto, CA, ²⁸Stanford University School of Medicine and Palo Alto VA Health Care System, Palo Alto, CA, ²⁹David Geffen School of Medicine, UCLA, Los Angeles, CA, ³⁰Pritzker School of Medicine, University of Chicago, Chicago, IL, ³¹Boston University Medical Center, BOSTON, MA, ³²NYU Langone Medical Center - NYU Hospital for Joint Diseases, Lake Success, NY, ³³Department of Medicine, University of Rochester Medical Center, Rochester, NY, ³⁴Yale School of Medicine, Westport, CT, ³⁵National Human Genome Research Institute (NHGRI), NIH, Bethesda, MD, ³⁶Johns Hopkins University School of Medicine, Baltimore, MD, ³⁷University of California San Francisco, Cedars-Sinai, West Hollywood, CA
Background/Purpose: African American (AA) patients have a higher prevalence of SSc than European Americans (EA). Adding to this health disparity, AA SSc patients are more…
Abstract Number: 1256 • ACR Convergence 2020
Mast Cells Contribute to the Development of Sialadenitis Associated with Sjögren’s Syndrome via Inducing Tissue Fibrosis by TGFβ Production
Shinjiro Kaieda¹, Kyoko Fujimoto¹ and Hiroaki Ida¹, ¹Kurume University School of Medicine, Kurume, Japan
Background/Purpose: Mast cells have been implicated in many immune-inflammatory disorders. They mediate a variety of inflammatory and fibrotic conditions, but their role in sialadenitis in…
Abstract Number: 1911 • ACR Convergence 2020
IL-11 Expression in Systemic Sclerosis Pulmonary Fibroblasts Is Mediated by Caspase-1
Caya McFalls¹ and Carol Artlett¹, ¹Drexel University College of Medicine, Philadelphia
Background/Purpose: Interleukin-11 (IL-11) has been shown to be associated with idiopathic pulmonary fibrosis, cardiac and kidney fibrosis. However, conflicting data shows IL-11 can be either…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].